Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.67 |
| ▸ | KIT | P10721 | 6/20 | 0.67 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.67 |
| ▸ | FLT4 | P35916 | 5/20 | 0.67 |
| ▸ | FLT3 | P36888 | 5/20 | 0.67 |
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.67 |
| ▸ | FLT1 | P17948 | 3/20 | 0.67 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.67 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.67 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.62 |
| ▸ | F13A1 | P00488 | 1/20 | 0.61 |
| ▸ | TGM2 | P21980 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | TYK2 | P29597 | 1/20 | 0.61 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10150437 | 0.89 | F13A1 (0.77) | KDRKITPDGFRAFLT4FLT3 | |
| SCHEMBL10150507 | 0.89 | F13A1 (0.77) | KDRKITPDGFRAFLT4FLT3 | |
| SCHEMBL10150038 | 0.89 | F13A1 (0.77) | KDRKITPDGFRAFLT4FLT3 | |
| SCHEMBL14293730 | 0.81 | HSP90AB1 (0.62) | KDRKITPDGFRAFLT4FLT3 | |
| Monocillin Ii Glycoside SCHEMBL30716073 | 0.80 | HSP90AB1 (0.50) | KDRKITPDGFRAFLT4FLT3 | |
| SCHEMBL15764588 | 0.80 | KDR (1.00) | KDRKITPDGFRAFLT4FLT3 | |
| SCHEMBL19418488 | 0.80 | HSP90AB1 (0.61) | KDRKITPDGFRAFLT4FLT3 | |
| SCHEMBL10187433 | 0.78 | HSP90AB1 (0.48) | KDRKITPDGFRAFLT4FLT3 | |
| SCHEMBL10150265 | 0.78 | MKNK2 (0.57) | KDRKITPDGFRAFLT4FLT3 | |
| SCHEMBL19418018 | 0.78 | HSP90AB1 (0.48) | KDRKITPDGFRAFLT4FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2136799-B1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | UNIV STRASBOURG (FR) | 2017-10-04 | — | — | EP | disclosed |
| US-8450305-B2 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2013-05-28 | — | — | US | disclosed |
| US-8450305-B2 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2013-05-28 | — | — | US | disclosed |
| US-8329683-B2 | Treatment of neurofibromatosis with radicicol and its derivatives | NEXGENIX PHARMACEUTICALS, LLC (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120077775-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-29 | — | — | US | disclosed |
| US-20120077775-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-29 | — | — | US | disclosed |
| US-8067412-B2 | analogs of natural products radicicol and pochonins; (oxirane or cyclopropan) 2-benzoxacyclo(di)tetradecin derivatives; inhibition of kinase phosphorylation activity and heat shock proteins; anticarcinogenic, antiinflammatory agent; neurodegenerative diseases; antiallergen | UNIVERSITE DE STRASBOURG (FR) | 2011-11-29 | — | — | US | disclosed |
| US-8067412-B2 | analogs of natural products radicicol and pochonins; (oxirane or cyclopropan) 2-benzoxacyclo(di)tetradecin derivatives; inhibition of kinase phosphorylation activity and heat shock proteins; anticarcinogenic, antiinflammatory agent; neurodegenerative diseases; antiallergen | UNIVERSITE DE STRASBOURG (FR) | 2011-11-29 | — | — | US | disclosed |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | NEXGENIX PHARMACEUTICALS HOLDINGS, INC. | 2010-11-18 | — | — | US | disclosed |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | NEXGENIX PHARMACEUTICALS HOLDINGS, INC. | 2010-11-18 | — | — | US | disclosed |
| WO-2008150302-A1 | TREATMENT OF NEUROFIBROMATOSIS WITH RADICICOL AND ITS DERIVATIVES | NEXGENIX PHARMACEUTICALS (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2008-06-19 | — | — | US | disclosed |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2008-06-19 | — | — | US | disclosed |
| WO-2008021213-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | WINSSINGER NICOLAS (FR) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077775-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | HSP90AB1, HSP90AA1, HSP90AB2P | KDR 1249/4885KIT 2869/4885PDGFRA 1158/4885 |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | HSP90AB2P, HSP90AA1, HSPA2 | KDR 801/4885KIT 4273/4885PDGFRA 900/4885 |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | HSP90AB1, HSP90AA1, HSP90AB2P | KDR 1249/4885KIT 2869/4885PDGFRA 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.